Electronic Portal Imaging Device Measurements Research Articles

Transit dosimetry of stereotactic body radiotherapy treatments with electronic portal dosimetry device in patient with spinal implant.

In recent years, the use of the Electronic Portal Imaging Device (EPID) as an in vivo dosimeter has become widespread. However, reports of EPID for stereotactic body radiotherapy (SBRT) applications is scarce. There is no data on this topic especially when there are high-density materials in the radiation field. In this study, we aimed to investigate the dose distributions of SBRT treatment plans in patients with spinal implants by transit EPID dosimetry. Implants were inserted in phantoms that mimic the vertebrae, and VMAT plans were created on the phantoms to deliver 16Gy radiation doses to the target in 1 fraction. Transit EPID measurements were performed for each irradiation. The results were compared with the treatment planning system using the gamma analysis method. According to the gamma analysis results, while the non-implant model met the acceptance criteria with a rate of 95.4%, the implanted models did not pass the test with results between the rates of 70% to 73%. In addition, while the dose difference in the isocenter was 1.3% for the non-implanted model, this difference was observed to be between 7 and 8% in the implanted models. Our study revealed that EPID can be used as transit dosimetry for the VMAT-SBRT applications. However, unacceptable dose differences were obtained by transit EPID dosimetry in the VMAT-SBRT applications of patients with an implant. In the treatment of such patients, alternative treatment methods should be preferred in which the interaction of the implants with radiation can be prevented.

The fast calibration model for dosimetry with an electronic portal imaging device.

The aim of this study was to develop an algorithm that corrects the image of an electronic portal imaging device (EPID) of a linear accelerator so that it can be used for dosimetric purposes, such as in vivo dosimetry or quality assurance for photon radiotherapy. For that purpose, the impact of the field size, phantom thickness, and the varying spectral photon distribution within the irradiation field on the EPID image was investigated. The EPID measurements were verified using reference measurements with ionization chambers. Therefore, absolute dose measurements with an ionization chamber and relative dose measurements with a detector array were performed. An EPID calibration and correction algorithm was developed to convert the EPID image to a dose distribution. The algorithm was validated by irradiating inhomogeneous phantoms using square fields as well as irregular IMRT fields. It was possible to correct the influence of the field size, phantom thickness on the EPID signal as well as the homogenization of the image profile by several correction factors within 0.6%. A gamma index analysis (3%, 3mm) of IMRT fields showed a pass rate of above 99%, when comparing to the planning system. The developed algorithm enables an online dose measurement with the EPID during the radiation treatment. The algorithm is characterized by a robust, non-iterative, and thus real-time capable procedure with little measuring effort and does not depend on system-specific parameters. The EPID image is corrected by multiplying three independent correction factors. Therefore, it can easily be extent by further correction factors for other influencing variables, so it can be transferred to other linear accelerators and EPID configurations.

Extending in aqua portal dosimetry with dose inhomogeneity conversion maps for accurate patient dose reconstruction in external beam radiotherapy.

Background and purposeIn aqua dosimetry with electronic portal imaging devices (EPIDs) allows for dosimetric treatment verification in external beam radiotherapy by comparing EPID-reconstructed dose distributions (EPID_IA) with dose distributions calculated with the treatment planning system in water-equivalent geometries. The main drawback of the method is the inability to estimate the dose delivered to the patient. In this study, an extension to the method is presented to allow for patient dose reconstruction in the presence of inhomogeneities.Materials and methodsEPID_IA dose distributions were converted into patient dose distributions (EPID_IA_MC) by applying a 3D dose inhomogeneity conversion, defined as the ratio between patient and water-filled patient dose distributions computed using Monte Carlo calculations. EPID_IA_MC was evaluated against dose distributions calculated with a collapsed cone convolution superposition (CCCS) algorithm and with a GPU‐based Monte Carlo dose calculation platform (GPUMCD) using non-transit EPID measurements of 25 plans. In vivo EPID measurements of 20 plans were also analyzed.ResultsIn the evaluation of EPID_IA_MC, the average γ-mean values (2% local/2mm, 50% isodose volume) were 0.70 ± 0.14 (1SD) and 0.66 ± 0.10 (1SD) against CCCS and GPUMCD, respectively. Percentage differences in median dose to the planning target volume were within 3.9% and 2.7%, respectively. The number of in vivo dosimetric alerts with EPID_IA_MC was comparable to EPID_IA.ConclusionsEPID_IA_MC accommodates accurate patient dose reconstruction for treatment disease sites with significant tissue inhomogeneities within a simple EPID-based direct dose back-projection algorithm, and helps to improve the clinical interpretation of both pre-treatment and in vivo dosimetry results.

Enhance dynamic wedge verification by using electronic portal imaging device

Objectives The purpose of this study was to verify the 80% enhanced dynamic wedge (EDW) beam profile using an electronic portal imaging device (EPID). Methods This study investigated symmetric and asymmetric field sizes using a 6 MV photon beam. Verification of the wedge output factor with an 80% beam profile was performed by comparing EPID measurements and treatment planning systems (TPS) calculations in both symmetric and asymmetric field sizes at different wedge angles (15, 30, 45, and 60 degrees). Results For the symmetric field size, the average difference between the measured and calculated beam profile was less than 2% (range 0.57-1.12%). For the asymmetric field size, the difference was also less than 2% (range 0.3-0.52%). Conclusion This study indicates that EPID can be used to verify the 80% enhanced dynamic wedge beam profile at different field sizes and wedge angles. The difference in beam profiles was less than 2% which is in accordance with AAPM TG no.142 recommendations.

Toward real-time verification for MLC tracking treatments using time-resolved EPID imaging.

In multileaf collimator (MLC) tracking, the MLC positions from the original treatment plan are continuously modified to account for intrafraction tumor motion. As the treatment is adapted in real time, there is additional risk of delivery errors which cannot be detected using traditional pretreatment dose verification. The purpose of this work is to develop a system for real-time geometric verification of MLC tracking treatments using an electronic portal imaging device (EPID). MLC tracking was utilized during volumetric modulated arc therapy (VMAT). During these deliveries, treatment beam images were taken at 9.57 frames per second using an EPID and frame grabber computer. MLC positions were extracted from each image frame and used to assess delivery accuracy using three geometric measures: the location, size, and shape of the radiation field. The EPID-measured field location was compared to the tumor motion measured by implanted electromagnetic markers. The size and shape of the beam were compared to the size and shape from the original treatment plan, respectively. This technique was validated by simulating errors in phantom test deliveries and by comparison between EPID measurements and treatment log files. The method was applied offline to images acquired during the LIGHT Stereotactic Ablative Body Radiotherapy (SABR) clinical trial, where MLC tracking was performed for 17 lung cancer patients. The EPID-based verification results were subsequently compared to post-treatment dose reconstruction. Simulated field location errors were detected during phantom validation tests with an uncertainty of 0.28mm (parallel to MLC motion) and 0.38mm (perpendicular), expressed as a root-mean-square error (RMSError ). For simulated field size errors, the RMSError was 0.47 cm2 and field shape changes were detected for random errors with standard deviation≥2.5mm. For clinical lung SABR deliveries, field location errors of 1.6mm (parallel MLC motion) and 4.9mm (perpendicular) were measured (expressed as a full-width-half-maximum). The mean and standard deviation of the errors in field size and shape were 0.0±0.3 cm2 and 0.3±0.1 (expressed as a translation-invariant normalized RMS). No correlation was observed between geometric errors during each treatment fraction and dosimetric errors in the reconstructed dose to the target volume for this cohort of patients. A system for real-time delivery verification has been developed for MLC tracking using time-resolved EPID imaging. The technique has been tested offline in phantom-based deliveries and clinical patient deliveries and was used to independently verify the geometric accuracy of the MLC during MLC tracking radiotherapy.

External validation of a hidden Markov model for gamma-based classification of anatomical changes in lung cancer patients using EPID dosimetry.

To externally validate a hidden Markov model (HMM) for classifying gamma analysis results of in vivo electronic portal imaging device (EPID) measurements into different categories of anatomical change for lung cancer patients. Additionally, the relationship between HMM classification and deviations in dose-volume histogram (DVH) metrics was evaluated. The HMM was developed at CHU de Québec (CHUQ), and trained on features extracted from gamma analysis maps of in vivo EPID measurements from 483 fractions (24 patients, treated with three-dimensional 3D-CRT or intensity modulated radiotherapy), using the EPID measurement of the first treatment fraction as reference. The model inputs were the average gamma value, standard deviation, and average value of the highest 1% of gamma values, all averaged over all beams in a fraction. The HMM classified each fraction into one of three categories: no anatomical change (Category 1), some anatomical change (no clinical action needed, Category 2) and severe anatomical change (clinical action needed, Category 3). The external validation dataset consisted of EPID measurements from 263 fractions of 30 patients treated at Maastro with volumetric modulated arc therapy (VMAT) or hybrid plans (containing both static beams and VMAT arcs). Gamma analysis features were extracted in the same way as in the CHUQ dataset, by using the EPID measurement of the first fraction as reference (γQ), and additionally by using an EPID dose prediction as reference (γM). For Maastro patients, cone beam computed tomography (CBCT) scans and image-guided radiotherapy (IGRT) classification of these images were available for each fraction. Contours were propagated from the planning CT to the CBCTs, and the dose was recalculated using a Monte Carlo dose engine. Dose-volume histogram metrics for targets and organs-at-risk (OARs: lungs, heart, mediastinum, spinal cord, brachial plexus) were extracted for each fraction, and compared to the planned dose. HMM classification of the external validation set was compared to threshold classification based on the average gamma value alone (a surrogate for clinical classification at CHUQ), IGRT classification as performed at Maastro, and differences in DVH metrics extracted from 3D dose recalculations on the CBCTs. The HMM achieved 65.4%/65.0% accuracy for γQ and γM, respectively, compared to average gamma threshold classification. When comparing HMM classification with IGRT classification, the overall accuracy was 29.7% for γQ and 23.2% for γM. Hence, HMM classification and IGRT classification of anatomical changes did not correspond. However, there is a trend towards higher deviations in DVH metrics with classification into higher categories by the HMM for large OARs (lungs, heart, mediastinum), but not for the targets and small OARs (spinal cord, brachial plexus). The external validation shows that transferring the HMM for anatomical change classification to a different center is challenging, but can still be valuable. The HMM trained at CHUQ cannot be used directly to classify anatomical changes in the Maastro data. However, it may be possible to use the model in a different capacity, as an indicator for changes in the 3D dose based on two-dimensional EPID measurements.

Use of Amorphous Silicon (ASi) Electronic Portal Imaging Devices for Other applications for Linear Accelerator Quality Assurance

The success of radiation therapy depends critically on the accuracy of patient alignment in treatment position day after day. Electronic portal imaging devices (EPIDs) are widely used to monitor patient position during daily radiotherapy sessions. To verify other applications for medical linear accelerator quality assurance (linac QA), images of a 10×10 cm² and 18×18 cm² open field were acquired. The EPID was positioned at a fixed detector distance of 150 cm. The wedge profile and wedge factors with high level of accuracy were demonstrated. The profiles acquired using EPID deviated in shape and magnitude by up to 16% from the ion chamber profiles. The use of EPID for linac QA could be simplified by improving the available software analysis tools, thus making it more efficient. The study showed that the EPID aSi500 has the potential to be used as a relative dosimeter, making it a very simple and efficient tool for daily QA. All EPID measurements were performed using the linear accelerator model Varian DMX. The physical characteristics measured in this work suggest that the SLIC-EPID can be an efficient tool for daily QA.

Two-dimensional EPID dosimetry for an MR-linac: Proof of concept.

At our institute, in vivo patient dose distributions are reconstructed for all treatments delivered using conventional linacs from electronic portal imaging device (EPID) transit images acquired during treatment using a simple back-projection model. Currently, the clinical implementation of MRI-guided radiotherapy systems, which aims for online and real-time adaptation of the treatment plan, is progressing. In our department, the MR-linac (Unity, Elekta AB, Stockholm, Sweden) is now in clinical use. The aim of this work is to demonstrate the feasibility of two-dimensional (2D) EPID dosimetric verification for the magnetic resonance (MR)-linac by comparing back-projected EPID doses to ionization chamber (IC) array dose distributions. Our conventional back-projection algorithm was adapted for the MR-linac. The most important changes involve modeling of the attenuation by and scatter from the cryostat. The commissioning process involved the acquisition of square field EPID measurements using various phantom setups (varying SSD, phantom thickness, and field size). Commissioning models were created for gantry 0°, 90°, and 180° and verified by comparing EPID-reconstructed 2D dose distributions to measurements made with the OCTAVIUS 1500 IC array (PTW, Freiburg, Germany) for two prostate and one rectum IMRT plans (25 beams total). The average of the γ parameters (y-mean and y-pass rate) and the dose difference at a reference point were reported. Due to their construction, the attenuation of couch, bridge, and cryostat shows a much stronger dependence on gantry angle in the MR-linac compared to conventional linacs. We present a method to correct for these effects. This method is validated by dose reconstruction of the 25 intensity-modulated radiation therapy beams recorded at a certain gantry angle using the model of another gantry angle, combined with the correction method. For dose verification performed at a gantry angle identical to the commissioned model, the average y-mean and y-pass rate values (3% global dose, 2mm, 10% isodose) were 0.37±0.07 and 98.1, 95% CI [98.1±2.4], respectively. The average dose difference at the reference point was -0.5%±1.8%. Verification at gantry angles different from the commissioned model (i.e., using the gantry angle dependent correction) reported 0.39±0.08 and 97.6, 95% CI [96.9, 98.3] average y-mean and y-pass rate values. The average dose difference at the reference point was -0.1%±1.8%. The EPID dosimetry back-projection model was successfully adapted for the MR-linac at gantry 0°, 90°, and 180°, accounting for the presence of the MRI housing between phantom (or patient) and the EPID. A method to account for the gantry angle dependence was also tested reporting similar results.

EPID sensitivity to delivery errors for pre-treatment verification of lung SBRT VMAT plans

PurposeTo study the sensitivity of an Electronic Portal Imaging Device (EPID) in detecting delivery errors for VMAT lung stereotactic body radiotherapy (SBRT) using the Collapsed Arc method. MethodsBaseline VMAT plans and plans with errors intentionally introduced were generated for 15 lung SBRT patients. Three types of errors were introduced by modifying collimator angles and multi-leaf collimator (MLC) field sizes (MLCFS) and MLC shifts by ±5, ±2, and ±1° or millimeters. A total of 103 plans were measured with EPID on an Elekta Synergy Linear Accelerator (Agility MLC) and compared to both the original treatment planning system (TPS) Collapsed Arc dose matrix and the no-error plan baseline EPID measurements. Gamma analysis was performed using the OmniPro-I'mRT (IBA Dosimetry) software and gamma criteria of 1%/1 mm, 2%/1 mm, 2%/2 mm, and 3%/3. ResultsWhen the error-introduced EPID measured dose matrices were compared to the TPS matrices, the majority of simulated errors were detected with gamma tolerance of 2%/1 mm and 1%/1 mm. When the error-introduced EPID measured dose matrices were compared to the baseline EPID measurements, all the MLCFS and MLC shift errors, and ±5°collimator errors were detected using 2%/1 mm and 1%/1 mm gamma criteria. ConclusionThis work demonstrates the feasibility and effectiveness of the collapsed arc technique and EPID for pre-treatment verification of lung SBRT VMAT plans. The EPID was able to detect the majority of MLC and the larger collimator errors with sensitivity to errors depending on the gamma tolerances.

P183] Replacement of EPID-based patient-specific QA by treatment analysis software

Purpose It is standard practice to perform QA of IMRT and VMAT plans by delivering the plans to the EPID (Electronic Portal Imaging Device) and comparing the measured dose to the calculated dose by an independent dose calculation engine prior to treatment. However, this procedure is both time consuming and reduces the patient throughput because the whole treatment must be delivered and measured using a clinical accelerator. In addition, noise and drift of the EPID require considerable extra resources to investigate false dose deviations and to perform repetitive EPID measurements. Accordingly, there is a need for a more streamlined QA approach with the same level of patient safety. Methods The Treatment Delivery Tool is an in house-developed C# application that can analyze both Varian Clinac and Varian TrueBeam treatment delivery log files. For each treatment the deviation between the delivered and planned fluence is calculated using the planned/actual MLC positions and the planned/actual MU for each time step in the log file. In addition, the application calculates all key technical parameters of the treatment delivery (e.g. max. MLC deviation, max. MU deviation, and max. MLC speed). Results The Treatment Delivery Tool automatically analyzes all daily treatments of an accelerator within one minute using a standard PC. Over a test period of two months 14 treatments with a significant deviation of the delivered fluence (more than 2% for more than 2% of the fluence area) were found. The deviations are related to a high MLC modulation (small MLC gap) and a large MU deviation. The test period also demonstrates that the Treatment Delivery Tool detects treatment errors with a much higher accuracy than possible with EPID-based QA. Conclusions The Treatment Delivery Tool is an effective and accurate tool for detecting dose delivery errors. In our department the application is complemented by an independent dose calculation by MobiusCalc (Mobius, USA) and a comprehensive accelerator QA program detecting any significant deviation between treatment delivery and data in the log file. This combined approach is very efficient and provides the same level of patient safety as for EPID-based patient-specific QA.

Automated EPID-based measurement of MLC leaf offset as a quality control tool

The multi-leaf collimator (MLC) dosimetric leaf gap (DLG) offset and transmission are measured parameters which influence the dosimetric accuracy of radiation therapy treatment plans. An international consortium developed an efficient method of automatically measuring the two-dimensional MLC DLG and transmission using the electronic portal imaging device (EPID) on multiple Varian TrueBeam linacs incorporating Millennium and high definition (HD) MLCs. Quality control was implemented as part of each test. Results were compiled including comparisons to baseline measurements and between machines. Validations were accomplished using ion chambers (IC) and a 2D IC array. Sensitivity was investigated by introducing deliberate leaf position offsets, repeatability was assessed, and performance was analyzed using statistical process control methods. The EPID measured DLG (EDLG) and transmission were consistently smaller than the IC measured DLG and transmission for all machines tested. EDLG variations across two dimensions averaged more than 0.24 mm for both Millennium and HD MLCs, demonstrating that leaf-to-leaf DLG variations should be assessed for both MLC types. The two-dimensional correlation coefficient between the IC array and EPID measurements was at least 0.937. A nearly linear relationship between changes in the EPID measured leaf gap and actual leaf positions was measured, with R2 > 0.999. EDLG results were analyzed as a difference relative to a baseline EDLG measurement for each machine, a metric we labeled the leaf offset constancy (LOC). The maximum change in LOC out of the 20 repeatability tests was −0.094 mm. The LOC QC process was found to be capable (Cpk > 1) for 4 machines using a ± 0.15 mm specification limit. LOC results showed that leaves may deviate from their reference positions at a level that approaches dosimetric significance for small stereotactic and highly modulated treatment fields, with average excursions measuring up to 0.21 mm for a Millennium MLC and 0.16 mm for a HD MLC. The effects of initialization, gantry angle, and common repairs are also reported.

Commission of volumetric modulated arc therapy with electronic portal image device

Objective To apply electronic portal imaging device (EPID) in the quality assurance of volumetric modulated arc therapy (VMAT) delivered by TrueBeam linear accelerator. Methods The Shaper software and Eclipse treatment planning system (TPS) were used to edit the VMAT plan delivered by TrueBeam linear accelerator. The EPID was used to evaluate the setup accuracy of multi-leaf collimator (MLC) and clinical dosimetry. TA: a field with a size of 0.5 cm×20.0 cm was exposed with gantry angles of 0°, 90°, and 270°, respectively; TB: the flatness and stability of the field were tested with different combinations of dose rate and gantry angle speed; TC: the setup accuracy of MLC was evaluated with or without rotation; TD: the accuracy of speed change control of MLC was evaluated with or without rotation; TE: the accuracy of simultaneous changes in dose rate and gantry angle speed was evaluated; TF: Clinical patients were evaluated. The Matlab software was used to analyze the results. Results TA: the full width at half maximum of superimposed fields exposed with gantry angles of 0°, 90°, and 270°was 0.39 mm larger than that of the field exposed with a gantry angle of 0°. TB: the difference in flatness was less than 0.5% between fields with different combinations of dose rate and gantry angle speed. TC: the maximum difference in field center was 0.45 mm between EPID measurement and TPS setting. TD: the maximum difference in MLC position was 0.69 mm between EPID measurement and TPS setting. TE: the maximum difference was 0.42 mm between fields. TF: for all the patients, the lowest γ passing rate was 96.4% according to the criterion of 3%/3 mm. Conclusions EPID is an accurate and convenient approach for VMAT quality assurance, which provides an option for physicists to reduce workload. Key words: Electronic portal image device; Volumetric modulated arc therapy; Quality control

Pixel response-based EPID dosimetry for patient specific QA.

Increasing use of high dose rate, flattening filter free (FFF), and/or small‐sized field beams presents a significant challenge to the medical physics community. In this work, we develop a strategy of using a high spatial resolution and high frame rate amorphous silicon flat panel electronic portal imaging device (EPID) for dosimetric measurements of these challenging cases, as well as for conventional external beam therapy. To convert a series of raw EPID‐measured radiation field images into water‐based dose distribution, a pixel‐to‐pixel dose–response function of the EPID specific to the linac is essential. The response function was obtained by using a Monte Carlo simulation of the photon transport in the EPID with a comprehensive calibration. After the raw image was converted into the primary incident photon fluence, the fluence was further convolved into a water‐based dose distribution of the dynamic field by using a pregenerated pencil‐beam kernel. The EPID‐based dosimetric measurement technique was validated using beams with and without flattening filter of all energies available in Varian TrueBeam STx™. Both regularly and irregularly shaped fields measured using a PTW 729 ion chamber array in plastic water phantom. The technique was also applied to measure the distribution for a total of 23 treatment plans of different energies to evaluate the accuracy of the proposed approach. The EPID measurements of square fields of 4 × 4 cm2 to 20 × 20 cm2, circular fields of 2–15 cm diameters, rectangular fields of various sizes, and irregular MLC fields were in accordance with measurements using a Farmer chamber and/or ion chamber array. The 2D absolute dose maps generated from EPID raw images agreed with ion chamber measurements to within 1.5% for all fields. For the 23 patient cases examined in this work, the average γ‐index passing rate were found to be 99.2 ± 0.6%, 97.4 ± 2.4%, and 72.6 ± 8.4%, respectively, for criterions of 3 mm/3%, 2 mm/2%, and 1 mm/1%. The high spatial resolution and high frame rate EPID provides an accurate and efficient dosimetric tool for QA of modern radiation therapy. Accurate absolute 2D dose maps can be generated from the system for an independent dosimetric verification of treatment delivery.

Technical Note: Experimental results from a prototype high-field inline MRI-linac.

The pursuit of real-time image guided radiotherapy using optimal tissue contrast has seen the development of several hybrid magnetic resonance imaging (MRI)-treatment systems, high field and low field, and inline and perpendicular configurations. As part of a new MRI-linac program, an MRI scanner was integrated with a linear accelerator to enable investigations of a coupled inline MRI-linac system. This work describes results from a prototype experimental system to demonstrate the feasibility of a high field inline MR-linac. The magnet is a 1.5 T MRI system (Sonata, Siemens Healthcare) was located in a purpose built radiofrequency (RF) cage enabling shielding from and close proximity to a linear accelerator with inline (and future perpendicular) orientation. A portable linear accelerator (Linatron, Varian) was installed together with a multileaf collimator (Millennium, Varian) to provide dynamic field collimation and the whole assembly built onto a stainless-steel rail system. A series of MRI-linac experiments was performed to investigate (1) image quality with beam on measured using a macropodine (kangaroo) ex vivo phantom; (2) the noise as a function of beam state measured using a 6-channel surface coil array; and (3) electron contamination effects measured using Gafchromic film and an electronic portal imaging device (EPID). (1) Image quality was unaffected by the radiation beam with the macropodine phantom image with the beam on being almost identical to the image with the beam off. (2) Noise measured with a surface RF coil produced a 25% elevation of background intensity when the radiation beam was on. (3) Film and EPID measurements demonstrated electron focusing occurring along the centerline of the magnet axis. A proof-of-concept high-field MRI-linac has been built and experimentally characterized. This system has allowed us to establish the efficacy of a high field inline MRI-linac and study a number of the technical challenges and solutions.

SU-G-BRB-10: New Generation of High Frame-Rate and High Spatial-Resolution EPID QA System for Full-Body MLC-Based Robotic Radiosurgery

Purpose: To systematically investigate an ultra-high spatial-resolution amorphous silicon flat-panel electronic portal imaging device (EPID) for MLC-based full-body robotic radiosurgery geometric and dosimetric quality assurance (QA). Methods: The high frame-rate and ultra-high spatial resolution EPID is an outstanding detector for measuring profiles, MLC-shaped radiosurgery field aperture verification, and small field dosimetry. A Monte Carlo based technique with a robotic linac specific response and calibration is developed to convert a raw EPID-measured image of a radiosurgery field into water-based dose distribution. The technique is applied to measure output factors and profiles for 6MV MLC-defined radiosurgery fields with various sizes ranging from 7.6mm×7.7mm to 100mm×100.1mm and the results are compared with the radiosurgery diode scan measurements in water tank. The EPID measured field sizes and the penumbra regions are analyzed to evaluate the MLC positioning accuracy. Results: For all MLC fields, the EPID measured output factors of MLC-shaped fields are in good agreement with the diode measurements. The mean output difference between the EPID and diode measurement is 0.05±0.87%. The max difference is −1.33% for 7.6mm×7.7mm field. The MLC field size derived from the EPID measurements are in good agreement comparing to the diode scan result. For crossline field sizes, the mean difference is −0.17mm±0.14mm with a maximum of −0.35mm for the 30.8mm×30.8mm field. For inline field sizes, the mean difference is +0.08mm±0.18mm with a maximum of +0.45mm for the 100mm×100.1mm field. The high resolution EPID is able to measure the whole radiation field, without the need to align the detector center perfectly at field center as diode or ion chamber measurement. The setup time is greatly reduced so that the whole process is possible for machine and patient-specific QA. Conclusion: The high spatial-resolution EPID is proved to be an accurate and efficient tool for QA of MLC-equipped robotic radiosurgery system.

SU‐F‐T‐230: A Simple Method to Assess Accuracy of Dynamic Wave Arc Irradiation Using An Electronic Portal Imaging Device and Log Files

Purpose:The Dynamic Wave Arc (DWA) technique, where the multi‐leaf collimator (MLC) and gantry/ring move simultaneously in a predefined non‐coplanar trajectory, has been developed on the Vero4DRT. The aim of this study is to develop a simple method for quality assurance of DWA delivery using an electronic portal imaging device (EPID) measurements and log files analysis.Methods:The Vero4DRT has an EPID on the beam axis, the resolution of which is 0.18 mm/pixel at the isocenter plane. EPID images were acquired automatically. To verify the detection accuracy of the MLC position by EPID images, the MLC position with intentional errors was assessed. Tests were designed considering three factors: (1) accuracy of the MLC position (2) dose output consistency with variable dose rate (160–400 MU/min), gantry speed (2.4–6°/s), ring speed (0.5–2.5°/s), and (3) MLC speed (1.6–4.2 cm/s). All the patterns were delivered to the EPID and compared with those obtained with a stationary radiation beam with a 0° gantry angle. The irradiation log, including the MLC position and gantry/ring angle, were recorded simultaneously. To perform independent checks of the machine accuracy, the MLC position and gantry/ring angle position were assessed using log files.Results:0.1 mm intentional error can be detected by the EPID, which is smaller than the EPID pixel size. The dose outputs with different conditions of the dose rate and gantry/ring speed and MLC speed showed good agreement, with a root mean square (RMS) error of 0.76%. The RMS error between the detected and recorded data were 0.1 mm for the MLC position, 0.12° for the gantry angle, and 0.07° for the ring angle.Conclusion:The MLC position and dose outputs in variable conditions during DWA irradiation can be easily detected using EPID measurements and log file analysis. The proposed method is useful for routine verification.This research is (partially) supported by the Practical Research for Innovative Cancer Control (15Ack0106151h0001) from Japan Agency for Medical Research and development, AMED. Authors Takashi Mizowaki and Masahiro Hiraoka have consultancy agreement with Mitsubishi Heavy Industries, Ltd., Japan.

SU‐F‐T‐476: Performance of the AS1200 EPID for Periodic Photon Quality Assurance

Purpose:To assess the dosimetric performance of a new amorphous silicon flat‐panel electronic portal imaging device (EPID) suitable for high‐intensity, flattening‐filter‐free delivery mode.Methods:An EPID‐based QA suite was created with automation to periodically monitor photon central‐axis output and two‐dimensional beam profile constancy as a function of gantry angle and dose‐rate. A Varian TrueBeamTM linear accelerator installed with Developer Mode was used to customize and deliver XML script routines for the QA suite using the dosimetry mode image acquisition for an aS1200 EPID. Automatic post‐processing software was developed to analyze the resulting DICOM images.Results:The EPID was used to monitor photon beam output constancy (central‐axis), flatness, and symmetry over a period of 10 months for four photon beam energies (6x, 15x, 6xFFF, and 10xFFF). EPID results were consistent to those measured with a standard daily QA check device. At the four cardinal gantry angles, the standard deviation of the EPID central‐axis output was <0.5%. Likewise, EPID measurements were independent for the wide range of dose rates (including up to 2400 mu/min for 10xFFF) studied with a standard deviation of <0.8% relative to the nominal dose rate for each energy. Also, profile constancy and field size measurements showed good agreement with the reference acquisition of 0° gantry angle and nominal dose rate. XML script files were also tested for MU linearity and picket‐fence delivery. Using Developer Mode, the test suite was delivered in <60 minutes for all 4 photon energies with 4 dose rates per energy and 5 picket‐fence acquisitions.Conclusion:Dosimetry image acquisition using a new EPID was found to be accurate for standard and high‐intensity photon beams over a broad range of dose rates over 10 months. Developer Mode provided an efficient platform to customize the EPID acquisitions by using custom script files which significantly reduced the time.This work was funded in part by Varian Medical Systems.

SU-G-TeP2-01: Can EPID Based Measurement Replace Traditional Daily Output QA On Megavoltage Linac?

Purpose: To investigate the long term stability and viability of using EPID-based daily output QA via in-house and vendor driven protocol, to replace conventional QA tools and improve QA efficiency. Methods: Two Varian TrueBeam machines (TB1&TB2) equipped with electronic portal imaging devices (EPID) were employed in this study. Both machines were calibrated per TG-51 and used clinically since Oct 2014. Daily output measurement for 6/15 MV beams were obtained using SunNuclear DailyQA3 device as part of morning QA. In addition, in-house protocol was implemented for EPID output measurement (10×10 cm fields, 100 MU, 100cm SID, output defined over an ROI of 2×2 cm around central axis). Moreover, the Varian Machine Performance Check (MPC) was used on both machines to measure machine output. The EPID and DailyQA3 based measurements of the relative machine output were compared and cross-correlated with monthly machine output as measured by an A12 Exradin 0.65cc Ion Chamber (IC) serving as ground truth. The results were correlated using Pearson test. Results: The correlations among DailyQA3, in-house EPID and Varian MPC output measurements, with the IC for 6/15 MV were similar for TB1 (0.83–0.95) and TB2 (0.55–0.67). The machine output for the 6/15MV beams on both machines showed a similar trend, namely an increase over time as indicated by all measurements, requiring a machine recalibration after 6 months. This drift is due to a known issue with pressurized monitor chamber which tends to leak over time. MPC failed occasionally but passed when repeated. Conclusion: The results indicate that the use of EPID for daily output measurements has the potential to become a viable and efficient tool for daily routine LINAC QA, thus eliminating weather (T,P) and human setup variability and increasing efficiency of the QA process.

MO‐AB‐BRA‐03: Development of Novel Real Time in Vivo EPID Treatment Verification for Brachytherapy

Purpose:High Dose Rate (HDR) brachytherapy treatments are employed worldwide to treat a wide variety of cancers. However, in vivo dose verification remains a challenge with no commercial dosimetry system available to verify the treatment dose delivered to the patient. We propose a novel dosimetry system that couples an independent Monte Carlo (MC) simulation platform and an amorphous silicon Electronic Portal Imaging Device (EPID) to provide real time treatment verification.Methods:MC calculations predict the EPID response to the photon fluence emitted by the HDR source by simulating the patient, the source dwell positions and times, and treatment complexities such as tissue compositions/densities and different applicators. Simulated results are then compared against EPID measurements acquired with ∼0.14s time resolution which allows dose measurements for each dwell position. The EPID has been calibrated using an Ir‐192 HDR source and experiments were performed using different phantoms, including tissue equivalent materials (PMMA, lung and bone). A source positioning accuracy of 0.2 mm, without including the afterloader uncertainty, was ensured using a robotic arm moving the source.Results:An EPID can acquire 3D Cartesian source positions and its response varies significantly due to differences in the material composition/density of the irradiated object, allowing detection of changes in patient geometry. The panel time resolution allows dose rate and dwell time measurements. Moreover, predicted EPID images obtained from clinical treatment plans provide anatomical information that can be related to the patient anatomy, mostly bone and air cavities, localizing the source inside of the patient using its anatomy as reference.Conclusion:Results obtained show the feasibility of the proposed dose verification system that is capable to verify all the brachytherapy treatment steps in real time providing data about treatment delivery quality and also applicator/structure motion during or between treatments.

Quantifying the performance of in vivo portal dosimetry in detecting four types of treatment parameter variations.

To quantify the ability of electronic portal imaging device (EPID) dosimetry used during treatment (in vivo) in detecting variations that can occur in the course of patient treatment. Images of transmitted radiation from in vivo EPID measurements were converted to a 2D planar dose at isocenter and compared to the treatment planning dose using a prototype software system. Using the treatment planning system (TPS), four different types of variability were modeled: overall dose scaling, shifting the positions of the multileaf collimator (MLC) leaves, shifting of the patient position, and changes in the patient body contour. The gamma pass rate was calculated for the modified and unmodified plans and used to construct a receiver operator characteristic (ROC) curve to assess the detectability of the different parameter variations. The detectability is given by the area under the ROC curve (AUC). The TPS was also used to calculate the impact of the variations on the target dose-volume histogram. Nine intensity modulation radiation therapy plans were measured for four different anatomical sites consisting of 70 separate fields. Results show that in vivo EPID dosimetry was most sensitive to variations in the machine output, AUC = 0.70 - 0.94, changes in patient body habitus, AUC = 0.67 - 0.88, and systematic shifts in the MLC bank positions, AUC = 0.59 - 0.82. These deviations are expected to have a relatively small clinical impact [planning target volume (PTV) D99 change <7%]. Larger variations have even higher detectability. Displacements in the patient's position and random variations in MLC leaf positions were not readily detectable, AUC < 0.64. The D99 of the PTV changed by up to 57% for the patient position shifts considered here. In vivo EPID dosimetry is able to detect relatively small variations in overall dose, systematic shifts of the MLC's, and changes in the patient habitus. Shifts in the patient's position which can introduce large changes in the target dose coverage were not readily detected.